Immunome, Inc. (IMNM)
Automate Your Wheel Strategy on IMNM
With Tiblio's Option Bot, you can configure your own wheel strategy including IMNM - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol IMNM
- Rev/Share 0.1447
- Book/Share 3.0947
- PB 5.2962
- Debt/Equity 0.0154
- CurrentRatio 12.1266
- ROIC -0.8215
- MktCap 1426667681.0
- FreeCF/Share -2.1396
- PFCF -7.6634
- PE -6.7147
- Debt/Assets 0.014
- DivYield 0
- ROE -0.8736
- Rating C
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 3
- P/B Score 3
- D/E Score 2
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | IMNM | Goldman | -- | Buy | -- | $26 | Sept. 22, 2025 |
| Initiation | IMNM | Craig Hallum | -- | Buy | -- | $26 | Sept. 5, 2025 |
| Initiation | IMNM | Lake Street | -- | Buy | -- | $23 | April 2, 2025 |
News
Immunome Presents Preclinical Data Showing Proprietary TOP1i ADC Payload HC74 Overcomes Multiple Mechanisms of ADC Resistance
Published: October 23, 2025 by: Business Wire
Sentiment: Neutral
BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, recently presented preclinical data showing its proprietary antibody-drug conjugate (ADC) payload HC74 overcomes multiple mechanisms of ADC resistance, including payload efflux and target heterogeneity. HC74 is a novel topoisomerase I inhibitor that serves as the payload in IM-1021, a ROR1-targeted ADC currently in a Phase 1 tr.
Read More
Immunome stock a ‘buy' on ‘rich pipeline' of oncology therapeutics: analysts
Published: September 23, 2025 by: Proactive Investors
Sentiment: Positive
Immunome, Inc (NASDAQ: IMNM) has a “rich pipeline of potential best and/or first-in-class targeted oncology therapeutics,” Goldman Sachs analysts wrote in a note to clients on Monday. They initiated coverage on Immunome stock with a ‘Buy' rating and 12-month target price of $26 per share.
Read More
Immunome (IMNM) Soars 6.0%: Is Further Upside Left in the Stock?
Published: July 01, 2025 by: Zacks Investment Research
Sentiment: Positive
Immunome (IMNM) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
Read More
Immunome (IMNM) Upgraded to Buy: Here's What You Should Know
Published: June 16, 2025 by: Zacks Investment Research
Sentiment: Positive
Immunome (IMNM) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Read More
Wall Street Analysts See a 158.17% Upside in Immunome (IMNM): Can the Stock Really Move This High?
Published: June 12, 2025 by: Zacks Investment Research
Sentiment: Positive
The average of price targets set by Wall Street analysts indicates a potential upside of 158.2% in Immunome (IMNM). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Read More
Wall Street Analysts Think Immunome (IMNM) Could Surge 188.57%: Read This Before Placing a Bet
Published: May 26, 2025 by: Zacks Investment Research
Sentiment: Positive
The average of price targets set by Wall Street analysts indicates a potential upside of 188.6% in Immunome (IMNM). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Read More
All You Need to Know About Immunome (IMNM) Rating Upgrade to Buy
Published: May 13, 2025 by: Zacks Investment Research
Sentiment: Positive
Immunome (IMNM) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Read More
Wall Street Analysts Believe Immunome (IMNM) Could Rally 249.93%: Here's is How to Trade
Published: May 08, 2025 by: Zacks Investment Research
Sentiment: Positive
The consensus price target hints at a 249.9% upside potential for Immunome (IMNM). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Read More
About Immunome, Inc. (IMNM)
- IPO Date 2020-10-02
- Website https://immunome.com
- Industry Biotechnology
- CEO Clay B. Siegall
- Employees 131